|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | PVP<2 | PVP>=2 | p | Total |
|  | n | Mean (µ±σ) | % | n | Mean (µ±σ) | % |  | n | Mean (µ±σ) | % |
| Age |  | 59,3 ± 12,6 |  |  | 66,1± 9,0 |  | 0,166 | - | 62,47± 11,42 | - |
| Gender Female / Male  | 10/6 |  | 62,5/37,5 | 8/6 |  | 57,1/42,9 | 1,00 | 18/12 | - | 60/40 |
| Previous infection  | 2 |  | 12,5 | 5 |  | 35,7 | 0,204 | 7 | - | 23,33 |
| Diagnosis |  |  |  |  |  |  | 0,675 |  |  |  |
|  Benign or Pre-malignant  | 3 |  | 18,8 | 4 |  | 28,6 |  | 7 | - | 23,33 |
|  Malignant | 13 |  | 81,3 | 10 |  | 71,4 |  | 23 | - | 76,67 |
| Hepatitis B | 1 |  | 6,7 | 0 |  | 0 | 1,00 | 1 | -  | 3,33 |
| Alcoholic consumption | 2 |  | 13,3 | 0 |  | 0 | 0,483 | 2 | - | 6,67 |
| Smoking | 5 |  | 33,3 | 1 |  | 7,1 | 0,169 | 6 | -  | 20 |
| Diabetes Mellitus | 4 |  | 26,7 | 3 |  | 21,4 | 1,00 | 7 | - | 23,33 |
| Body mass index |  | 26,6 ± 5,1 |  |  | 26,95 ± 3,8 |  | 0,918 | - | 26,78 ± 4,48 | - |
| Karnofsky score (%) | 13(100%)2 (90%)1(80%) |  |  | 8(100%)3(90%)3(80%) |  |  | 0,240 | - | ⸸MED:100 | - |
| ASA\* (median) |  | 2 |  |  | 2 |  | 0,728 | - | 2 | - |
| FLR \*\* |  | 0,69 ±0,18 |  |  | 0,61 ±0,18 |  | 0,257 | - | 0,65 ± 0,18 | - |
| Surgical procedures |  |  |  |  |  |  |  |  |  |  |
| Multiple MTX\*\*\* / segmentectomy | 2 |  |  | 0 |  |  |  | 2 | - | 6,67 |
| Bisegmentectomy  | 3 |  |  | 3 |  |  |  | 6 | - | 20 |
| Trisegmentectomy  | 2 |  |  | 1 |  |  |  | 3 | - | 10 |
|  Left hepatectomy  | 3 |  |  | 2 |  |  |  | 5 | - | 16,67 |
|  Left hepatectomy + segmentectomy I | 1 |  |  | 1 |  |  |  | 2 | - | 6,67 |
|  Right hepatectomy  | 3 |  |  | 5 |  |  |  | 8 | - | 26,67 |
|  Right hepatectomy + segmentectomy I | 1 |  |  | 0 |  |  |  | 1 | - | 3,33 |
|  Central hepatectomy  | 1 |  |  | 1 |  |  |  | 2 | - | 6,67 |
|  ALPPS± | 0 |  |  | 1 |  |  |  | 1 | - | 3,33 |
| Morbidity Mortality |  |  |  |  |  |  |  |  |  |  |
| without complications | 5 |  | 31,3 | 2 |  | 14,2 |  | 7 | - | 23,33 |
| Hepatic failure  |  |  |  |  |  |  |  |  |  |  |
| ISGLS criteria | 4 |  |  | 0 |  |  |  | 4 |  | 13,33 |
| 50-50 criteria | 2 |  |  | 0 |  |  |  | 2 |  | 6,67 |
| Clavien Dindo Score |  |  |  |  |  |  |  |  |  |  |
|  - Grade I | 4 |  | 25  | 2 |  | 14,2 |  | 6 | - | 20 |
|  - Grade II | 4 |  | 25 | 3 |  | 21,4 |  | 7 | - | 23,33 |
|  - Grade IIIA | 1 |  | 6,3 | 3 |  | 21,4 |  | 4 | - | 13,33 |
|  - Grade IIIB | 1 |  | 6,3 | 1 |  | 7,1 |  | 2 | - | 6,67 |
|  - Grade IV | 1 |  | 6,3 | 0 |  | 0 |  | 1 | - | 3,33 |
|  - Grade V (Mortality in the first 90 days) | 0 |  | 0 | 3 |  | 21,4 |  | 3 | - | 10 |

TABLE 1 – Clinical characteristics of the patients included

\*ASA=American Society of Anaesthesiologists score; ⸸MED = median; \*\*FLR= Future liver remnant; \*\*\*MTX=metastasectomies; **±**ALLPS= Associating liver partition and portal vein ligation for staged hepatectomy.